行情

CVM

CVM

CEL SCI
AMEX

实时行情|Nasdaq Last Sale

18.32
+0.32
+1.78%
盘前: 19.10 +0.78 +4.26% 08:35 03/05 EST
开盘
18.23
昨收
18.00
最高
18.64
最低
16.83
成交量
2,551
成交额
--
52周最高
40.91
52周最低
8.10
市值
7.42亿
市盈率(TTM)
-20.8680
分时
5日
1月
3月
1年
5年
克莱默对Equinix,Walgreens Boots Alliance和CEL-SCI发表意见
Jim Cramer said on CNBC's "Mad Money Lightning Round" that Equinix Inc (NASDAQ: EQIX) is a real estate investment trust and right now, with the interest rates going higher, people don'
Benzinga · 41分钟前
克拉默的闪电之旅:我不推荐Equinix
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
CNBC.com · 12小时前
CEL-SCI第一季度每股收益($ 0.21)从去年同期的(0.16)下降
CEL-SCI (AMEX:CVM) reported quarterly losses of $(0.21) per share. This is a 31.25 percent decrease over losses of $(0.16) per share from the same period last year.
Benzinga · 02/16 14:05
西尼罗河病毒测试市场全球趋势,市场份额,行业规模,增长,机会和市场预测2020至2027
Feb 16, 2021 (Market Insight Reports) -- The report for West Nile Virus Testing offers an assiduous analysis of contemporary market trends, driving factors,...
Market Insight Reports · 02/16 13:45
按需求,销售额,收入,毛利率,地理区域以及到2027年的预测增长的2021年西尼罗河病毒感染医学市场
Feb 03, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." “West Nile Virus Infections Medicine...
The Express Wire · 02/03 08:37
Covid-19影响:痘病毒感染药物市场将在2020年后以更快的速度增长|财务分析与预测
Jan 28, 2021 (MarketResearch.biz via Comtex) -- Poxviridae Infections Drug Businesses must navigate the financial and operational challenges of coronavirus...
marketresearch.biz · 01/28 09:25
CEL-SCI Corporation向股东致函(全文)
CEL-SCI Corporation Issues Letter to Shareholders CEL-SCI Corporation (NYSE:CVM) today issued a letter to its shareholders. Dear Fellow Shareholders: Happy new year to all of you. As we embark on 2021, I
Benzinga · 01/04 14:18
Cel-Sci不应依赖于截至2019年12月31日,2020年3月31日和2020年6月30日的Qtr的季度报告中的财务报表
On December 23, 2020, the board of directors (the “Board”) of CEL-SCI Corporation (the “Company”), in consultation with management, concluded that the Company’s previously issued unaudited
Benzinga · 2020/12/29 22:07
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解CVM最新的财务预测,通过CVM每股收益,每股净资产,每股现金流等数据分析CEL SCI近期的经营情况,然后做出明智的投资选择。
分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测CVM价格均价为23.00,最高价位23.00,最低价为23.00。
EPS
机构持股
总机构数: 69
机构持股: 585.04万
持股比例: 14.43%
总股本: 4,052.93万
类型机构数股数
增持
19
265.68万
建仓
30
49.35万
减持
4
17.75万
平仓
3
24.38万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
-1.53%
制药与医学研究
-2.13%
高管信息
Chief Executive Officer/Director/Treasurer
Geert Kersten
Senior Vice President/Secretary
Patricia Prichep
Senior Vice President
John Cipriano
Senior Vice President
Daniel Zimmerman
Chief Scientific Officer
Eyal Talor
Independent Director
Bruno Baillavoine
Independent Director
Robert Watson
Independent Director
Peter Young
暂无数据
CVM 简况
CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy under development for treatment of certain head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus and human papillomavirus co-infected patients and Ligand Epitope Antigen Presentation System (L.E.A.P.S.) technology, with over two investigational therapies, LEAPS-H1N1-DC, a product candidate under development for treatment of pandemic influenza in hospitalized patients, and CEL-2000 and CEL-4000, vaccine product candidates under development for treatment of rheumatoid arthritis.

微牛提供CEL-SCI Corporation(AMEX-CVM)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CVM股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CVM股票基本功能。